Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Change in Acquisitions & Divestments (2016 - 2023)

Historic Change in Acquisitions & Divestments for Cartesian Therapeutics (RNAC) over the last 7 years, with Q1 2023 value amounting to $28.3 million.

  • Cartesian Therapeutics' Change in Acquisitions & Divestments rose 18254.0% to $28.3 million in Q1 2023 from the same period last year, while for Dec 2023 it was $28.3 million, marking a year-over-year increase of 4342.13%. This contributed to the annual value of $28.3 million for FY2023, which is 4342.13% up from last year.
  • Cartesian Therapeutics' Change in Acquisitions & Divestments amounted to $28.3 million in Q1 2023, which was up 18254.0% from $5.7 million recorded in Q4 2022.
  • Cartesian Therapeutics' Change in Acquisitions & Divestments' 5-year high stood at $28.3 million during Q1 2023, with a 5-year trough of $2.0 million in Q1 2019.
  • Its 4-year average for Change in Acquisitions & Divestments is $9.0 million, with a median of $6.4 million in 2021.
  • Per our database at Business Quant, Cartesian Therapeutics' Change in Acquisitions & Divestments crashed by 8675.97% in 2019 and then surged by 18254.0% in 2023.
  • Quarter analysis of 4 years shows Cartesian Therapeutics' Change in Acquisitions & Divestments stood at $11.5 million in 2019, then fell by 13.04% to $10.0 million in 2021, then plummeted by 43.0% to $5.7 million in 2022, then soared by 395.68% to $28.3 million in 2023.
  • Its last three reported values are $28.3 million in Q1 2023, $5.7 million for Q4 2022, and $4.0 million during Q3 2022.